GlassScriptPhysician profile
Scott D Mueller
NPI 1821034158
$16,413.89
in general payments reported to CMS, 2019-2025
44 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $1,418 · 2021: $3,054 · 2022: $2,488 · 2023: $3,694 · 2024: $2,924 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,453.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,964.51 | 2021-2025 | |
| Novo Nordisk INC | $2,305.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,865.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $924.06 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $920.86 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $820.49 | 2019-2025 | |
| Merz North America, INC. | $787.40 | 2021-2023 | |
| Amgen INC. | $785.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $523.11 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $409.08 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $386.76 | 2022 | |
| Allergan, INC. | $339.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $323.48 | 2019-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $321.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.44 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $261.66 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $254.53 | 2019-2024 | Eliquis, Camzyos |
| Sanofi Pasteur INC. | $186.47 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $177.24 | 2021-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Exact Sciences Corporation | $174.67 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $173.29 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $165.04 | 2020-2024 | Ajovy |
| Molnlycke Health Care US, LLC | $156.83 | 2024 | Mepilex Border Flex, Exufiber Ag+, Mepilex Ag |
| Supernus Pharmaceuticals, INC. | $124.14 | 2023-2024 | Qelbree |
| Indivior INC. | $110.47 | 2019-2024 | Sublocade |
| Almatica Pharma LLC | $76.91 | 2022-2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $67.99 | 2023-2024 | Quviviq |
| Daiichi Sankyo INC. | $67.34 | 2019-2023 | Injectafer |
| Ironshore Pharmaceuticals INC. | $64.14 | 2019 | |
| Vanda Pharmaceuticals INC. | $57.44 | 2025 | Fanapt |
| Biodelivery Sciences International, INC. | $47.52 | 2019-2021 | |
| Esperion Therapeutics, INC. | $46.99 | 2021 | |
| Inspire Medical Systems, INC. | $42.36 | 2024-2025 | Inspire |
| Cequr Corporation | $28.88 | 2023-2024 | Cequr Simplicity |
| Kaleo, INC. | $20.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.91 | 2020 | |
| Braeburn INC. | $18.62 | 2025 | Brixadi |
| Orexo US, INC. | $16.87 | 2021 | |
| Adlon Therapeutics L.P. | $14.48 | 2020 | |
| Vertiflex, INC. | $13.79 | 2019 | |
| Eisai INC. | $13.64 | 2020 | |
| Galderma Laboratories, L.P. | $13.48 | 2024 | |
| Scilex Pharmaceuticals INC. | $12.25 | 2019 | |
| Shire North American Group INC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.